Literature DB >> 30506871

Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.

Dadi A Srinivasarao1, Garima Lohiya1, Dhirendra S Katti1.   

Abstract

The eye consists of sensitive, compactly adjoined tissue structures which act as strong physical (static) and physiological (dynamic) barriers that prevent entry of foreign bodies into the eye. Together, these barriers reduce the bioavailability of topically and intraocularly administered medicaments thus demanding frequent drug administration for the treatment of chronic eye diseases. Hence, development of drug delivery systems (DDS) that can be retained in ocular tissues for longer durations can help to reduce the frequency of drug administration, whereas, delivery systems that traverse through ocular barriers may offer higher bioavailability of administered drugs to otherwise inaccessible ocular tissues. These objectives can be partially/fully achieved using nanoparticulate/colloidal DDS. Colloidal DDS, due to their nanodimensions, undergo internalization by cells which enables transport of drugs through ocular barriers. Furthermore, nanoparticles can prolong duration of drug release and can increase residence time of entrapped cargo molecules in ocular tissues. Together, these aspects facilitate a higher bioavailability, prolonged therapeutic effect and reduced frequency of drug administration for the effective treatment of chronic ocular diseases. Hence, nanocarriers have been widely explored for ophthalmic drug delivery applications. In this review, we discuss the anatomy of ocular tissues along with their barrier properties. We then discuss ocular diseases along with the various routes of drug administration and pathways of drug transport in the eye. The next section discusses the influence of physicochemical properties of therapeutic molecules on their ocular distribution and conventional and advanced (nanoparticulate/colloidal DDS) drug formulations that are used for the treatment of ocular diseases. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  colloidal drug delivery systems; nanomedicine; nanoparticles; ocular diseases; ocular drug delivery

Mesh:

Substances:

Year:  2018        PMID: 30506871     DOI: 10.1002/wnan.1548

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  10 in total

Review 1.  Current approaches of nanomedicines in the market and various stage of clinical translation.

Authors:  Xiaoting Shan; Xiang Gong; Jie Li; Jingyuan Wen; Yaping Li; Zhiwen Zhang
Journal:  Acta Pharm Sin B       Date:  2022-03-01       Impact factor: 14.903

2.  Chitosan Nanoparticles for Meloxicam Ocular Delivery: Development, In Vitro Characterization, and In Vivo Evaluation in a Rabbit Eye Model.

Authors:  Hebatallah B Mohamed; Mohamed Ali Attia Shafie; Aml I Mekkawy
Journal:  Pharmaceutics       Date:  2022-04-20       Impact factor: 6.525

Review 3.  An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.

Authors:  Chenchen Zhang; Yuan Yin; Jing Zhao; Yanxia Li; Yuanping Wang; Zhaoying Zhang; Lingzhi Niu; Yajuan Zheng
Journal:  Int J Nanomedicine       Date:  2022-10-19

Review 4.  Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation.

Authors:  Felipe M González-Fernández; Annalisa Bianchera; Paolo Gasco; Sara Nicoli; Silvia Pescina
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

Review 5.  Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.

Authors:  Alexander Vaneev; Victoria Tikhomirova; Natalia Chesnokova; Ekaterina Popova; Olga Beznos; Olga Kost; Natalia Klyachko
Journal:  Int J Mol Sci       Date:  2021-11-16       Impact factor: 5.923

Review 6.  Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.

Authors:  Mehrdad Afarid; Shirin Mahmoodi; Roghayyeh Baghban
Journal:  J Nanobiotechnology       Date:  2022-08-02       Impact factor: 9.429

Review 7.  Nanoparticles in ocular applications and their potential toxicity.

Authors:  Cao Yang; Junling Yang; Ao Lu; Jing Gong; Yuanxing Yang; Xi Lin; Minghui Li; Haiwei Xu
Journal:  Front Mol Biosci       Date:  2022-07-15

8.  Aqueous Humour Ofloxacin Concentration after Topical Instillation in Patients with Dry Eye Disease.

Authors:  Konstantinos Kagkelaris; Mohamed A El Mubarak; Panagiotis Plotas; Dimitris Panaretos; George D Panayiotakopoulos; Gregory B Sivolapenko; Constantinos D Georgakopoulos
Journal:  Medicina (Kaunas)       Date:  2022-08-01       Impact factor: 2.948

9.  In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation.

Authors:  Blanca Lorenzo-Veiga; Patricia Diaz-Rodriguez; Carmen Alvarez-Lorenzo; Thorsteinn Loftsson; Hakon Hrafn Sigurdsson
Journal:  Nanomaterials (Basel)       Date:  2020-04-09       Impact factor: 5.076

Review 10.  Stimuli-Responsive Polymers for Transdermal, Transmucosal and Ocular Drug Delivery.

Authors:  Dmitriy Berillo; Zharylkasyn Zharkinbekov; Yevgeniy Kim; Kamila Raziyeva; Kamila Temirkhanova; Arman Saparov
Journal:  Pharmaceutics       Date:  2021-12-01       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.